Celsion Corporation Reports 2021 Financial Results and Provides Business Update
March 31, 2022 08:30 ET | Celsion Corporation
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE)...
Vallon Pharmaceuticals to Participate at the 5th Annual Neuroscience Innovation Forum
March 23, 2022 08:00 ET | Vallon Pharmaceuticals Inc.
David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel, today, March 23rd at 9:00 AM ET Philadelphia, PA, March 23, 2022 (GLOBE NEWSWIRE) --...
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344
March 10, 2022 08:00 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy...
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update
February 14, 2022 16:15 ET | Vallon Pharmaceuticals Inc.
- Topline data for pivotal abuse study of the Company’s lead investigational program ADAIR expected this quarter - Second development program, ADMIR, continues to advance with...
Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors
January 05, 2022 08:30 ET | Lixte Biotechnology Holdings, Inc.
Outside research shows that in models of colorectal, triple-negative breast and pancreatic cancer, LB-100 induces molecular changes that render the cancers more vulnerable to immunotherapy ...
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 08:05 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
Cocrystal Pharma Presents Preclinical Data from COVID-19 Antiviral Programs and Outlines Near-Term Clinical Plans at the World Antiviral Congress 2021
December 01, 2021 16:05 ET | Cocrystal Pharma, Inc.
Unveils designs for Phase 1 and 2 studies with intranasal/pulmonary and oral SARS-CoV-2 protease inhibitors; trial initiations expected in 2022 BOTHELL, Wash., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development Programs and Milestones
November 15, 2021 08:00 ET | Cocrystal Pharma, Inc.
Submitted pre-IND briefing package to the FDA for intranasal/pulmonary CDI-45205 for the treatment of COVID-19 and sets goal of initiating IND-enabling study and Phase 1 in 2022Advance oral COVID-19...
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
November 11, 2021 08:05 ET | Vallon Pharmaceuticals Inc.
- Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov. 11, 2021...
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
November 01, 2021 08:35 ET | Vallon Pharmaceuticals Inc.
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant...